Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet the pharmaceutical industry’s needs in this area.
After slowing in 2012-13, Mexico’s pharmaceutical sector is expected to grow on average 5.6 percent rising from USD 16.4 billion in 2013 to 21.5 billion in 2018. Could you please tell to our international readers what steps the industry needs to take to keep performing at this level?
"The existing gap between the prices of generics, brand-generics and drugs from the innovator brands is not sustainable in the mid-term. Prices must be balanced in order to increase the value of the industry augmenting the operative margins of companies."
